Study protocol for an observational study to evaluate an accelerated chest pain pathway using point-of-care troponin in New Zealand rural and primary care populations.


Journal

Journal of primary health care
ISSN: 1172-6156
Titre abrégé: J Prim Health Care
Pays: Australia
ID NLM: 101524060

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 15 07 2019
accepted: 15 03 2020
entrez: 30 6 2020
pubmed: 1 7 2020
medline: 2 6 2021
Statut: ppublish

Résumé

INTRODUCTION Accelerated diagnostic chest pain pathways are used widely in urban New Zealand hospitals. These pathways use laboratory-based troponin assays with good analytical precision. Widespread implementation has not occurred in many of New Zealand's rural hospitals and general practices as they are reliant on point-of-care troponin assays, which are less sensitive and precise. An accelerated chest pain pathway using point-of-care troponin has been adapted for use in rural settings. A pilot study in a low-risk rural population showed no major adverse cardiac events at 30 days. A larger study is required to be confident that the pathway is safe. AIMS To assess the safety and effectiveness of an accelerated chest pain pathway adapted for rural settings and general practice using point-of-care troponin to identify low-risk patients and allow early discharge. METHODS This is a prospective observational study of an accelerated chest pain pathway using point-of-care troponin in rural hospitals and general practices in New Zealand. A total of 1000 patients, of whom we estimate 400 will be low risk, will be enrolled in the study. OUTCOME MEASURES The primary outcome is the proportion of patients identified by the pathway as low risk for a 30-day major adverse cardiac event. Secondary outcomes include the proportion of low-risk patients who were discharged directly from general practice or rural hospitals, the proportion of patients reclassified as having acute myocardial infarction by the pathway and the proportion of patients with low and intermediate risk safely managed in the rural hospital.

Identifiants

pubmed: 32594980
pii: HC19059
doi: 10.1071/HC19059
doi:

Substances chimiques

Troponin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-138

Auteurs

Rory Miller (R)

Department of General Practice and Rural Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; and Corresponding author. Email: Rory.miller@otago.ac.nz.

Joanna Young (J)

Department of General Practice and Rural Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Garry Nixon (G)

Cardiology, Canterbury DHB, Christchurch Hospital, Christchurch and Department of Medicine, University of Otago - Christchurch, Christchurch, New Zealand.

John W Pickering (JW)

Medicine, University of Otago - Christchurch and Emergency Department, Christchurch Hospital and Department of Medicine, University of Otago, Christchurch, New Zealand.

Tim Stokes (T)

Department of General Practice and Rural Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Robin Turner (R)

Centre for Biostatistics, Division of Health Sciences, University of Otago, Dunedin, New Zealand.

Gerard Devlin (G)

Tairawhiti DHB, Gisborne, New Zealand.

Antony Watson (A)

Emergency Care Foundation, St Albans, Christchurch, New Zealand.

Marc Gutenstein (M)

Department of General Practice and Rural Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; and Rural Health Academic Centre Ashburton, University of Otago and Christchurch and Emergency Department, Nelson Hospital, Nelson, New Zealand.

Tim Norman (T)

Project Office, Midlands Regional Health Network Charitable Trust, Hamilton, New Zealand.

Peter Myles George (PM)

Chemical pathology, PathoGene, Merivale, Christchurch, New Zealand.

Stephen Du Toit (S)

Biochemistry, Waikato DHB. Biochemistry Department, Waikato Hospital, Hamilton, New Zealand.

Martin Than (M)

Emergency Department, Canterbury DHB, Christchurch Hospital, Christchurch, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH